{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T14:19:41Z","timestamp":1795184381955,"version":"4.10.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-025-03913-6","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T10:42:46Z","timestamp":1738838566000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Adverse events in the nervous system associated with blinatumomab: a real-world study"],"prefix":"10.1186","volume":"23","author":[{"given":"Wen","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanfan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengzi","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianhuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"3913_CR1","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1200\/JCO.2010.30.1382","volume":"29","author":"R Bassan","year":"2011","unstructured":"Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29:532\u201343.","journal-title":"J Clin Oncol"},{"key":"3913_CR2","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O","volume":"86","author":"DA Thomas","year":"1999","unstructured":"Thomas DA, Kantarjian H, Smith TL, Koller C, Cortes J, O\u2019Brien S, et al. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer. 1999;86:1216\u201330.","journal-title":"Cancer"},{"key":"3913_CR3","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary \u00c9, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"3913_CR4","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","volume":"109","author":"AK Fielding","year":"2007","unstructured":"Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study. Blood. 2007;109:944\u201350.","journal-title":"Blood"},{"key":"3913_CR5","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.3109\/10428194.2011.559668","volume":"52","author":"S Raponi","year":"2011","unstructured":"Raponi S, De Propris MS, Intoppa S, Milani ML, Vitale A, Elia L, et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma. 2011;52:1098\u2013107.","journal-title":"Leuk Lymphoma"},{"key":"3913_CR6","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-15-0612","volume":"21","author":"D Przepiorka","year":"2015","unstructured":"Przepiorka D, Ko CW, Deisseroth A, Yancey CL, Candau-Chacon R, Chiu HJ, et al. FDA approval: blinatumomab. Clin Cancer Res. 2015;21:4035\u20139.","journal-title":"Clin Cancer Res"},{"key":"3913_CR7","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s10637-015-0289-4","volume":"33","author":"JB Kaplan","year":"2015","unstructured":"Kaplan JB, Grischenko M, Giles FJ. Blinatumomab for the treatment of acute lymphoblastic leukemia. Invest New Drugs. 2015;33:1271\u20139.","journal-title":"Invest New Drugs"},{"key":"3913_CR8","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1634\/theoncologist.2018-0179","volume":"23","author":"ED Pulte","year":"2018","unstructured":"Pulte ED, Vallejo J, Przepiorka D, Nie L, Farrell AT, Goldberg KB, et al. FDA supplemental approval: blinatumomab for treatment of relapsed and refractory precursor B-cell acute lymphoblastic leukemia. Oncologist. 2018;23:1366\u201371.","journal-title":"Oncologist"},{"key":"3913_CR9","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","volume":"120","author":"N G\u00f6kbuget","year":"2012","unstructured":"G\u00f6kbuget N, Stanze D, Beck J, Diedrich H, Horst HA, H\u00fcttmann A, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120:2032\u201341.","journal-title":"Blood"},{"key":"3913_CR10","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.beha.2018.03.004","volume":"31","author":"MB Leick","year":"2018","unstructured":"Leick MB, Maus MV. Toxicities associated with immunotherapies for hematologic malignancies. Best Pract Res Clin Haematol. 2018;31:158\u201365.","journal-title":"Best Pract Res Clin Haematol"},{"key":"3913_CR11","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1111\/jcpt.13741","volume":"47","author":"P Mocquot","year":"2022","unstructured":"Mocquot P, Mossazadeh Y, Lapierre L, Pineau F, Despas F. The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials. J Clin Pharm Ther. 2022;47:1337\u201351.","journal-title":"J Clin Pharm Ther"},{"key":"3913_CR12","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s40264-023-01345-w","volume":"46","author":"V Giunchi","year":"2023","unstructured":"Giunchi V, Fusaroli M, Hauben M, Raschi E, Poluzzi E. Challenges and opportunities in accessing and analysing FAERS data: a call towards a collaborative approach. Drug Saf. 2023;46:921\u20136.","journal-title":"Drug Saf"},{"key":"3913_CR13","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1080\/14740338.2020.1799975","volume":"19","author":"L Peng","year":"2020","unstructured":"Peng L, Xiao K, Ottaviani S, Stebbing J, Wang YJ. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib. Expert Opin Drug Saf. 2020;19:1505\u201311.","journal-title":"Expert Opin Drug Saf"},{"issue":"18","key":"3913_CR14","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.jacc.2021.08.044","volume":"78","author":"G Adam","year":"2021","unstructured":"Adam G, Elad M, David B, Jennifer EL, Joerg H, Joshua F, et al. Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy. J Am Coll Cardiol. 2021;78(18):1800\u201313.","journal-title":"J Am Coll Cardiol"},{"issue":"59","key":"3913_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101967","volume":"21","author":"CZ Zhou","year":"2023","unstructured":"Zhou CZ, Peng SK, Lin AQ, Jiang AM, Peng YX, Gu TQ, et al. Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. EClinicalMedicine. 2023;21(59): 101967.","journal-title":"EClinicalMedicine"},{"key":"3913_CR16","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1111\/cns.14215","volume":"29","author":"YM Shu","year":"2023","unstructured":"Shu YM, Ding YL, Liu LL, Zhang QL. Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system. CNS Neurosci Ther. 2023;29:2705\u201316.","journal-title":"CNS Neurosci Ther"},{"key":"3913_CR17","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3913_CR18","doi-asserted-by":"publisher","first-page":"4560","DOI":"10.1007\/s00415-022-11117-8","volume":"269","author":"U Pensato","year":"2022","unstructured":"Pensato U, Muccioli L, Zinzani PL, Angelo RD, Pierucci E, Casadei B, et al. Fulminant cerebral edema following CAR T-cell therapy: case report and pathophysiological insights from literature review. J Neurol. 2022;269:4560\u20133.","journal-title":"J Neurol"},{"key":"3913_CR19","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1182\/blood-2021-146882","volume":"138","author":"J Zurko","year":"2021","unstructured":"Zurko J, Xu H, Chaney K, Fenske TS, Hamadani M, Schneider D, et al. Bispecific LV20.19 CAR T-cells expanded in IL-7 and IL-15 have greater polyfunctionality and polyfunctional strength than CAR T-cells expanded in IL-2. Blood. 2021;138:1728.","journal-title":"Blood"},{"key":"3913_CR20","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1182\/blood-2023-187295","volume":"142","author":"T Kewan","year":"2023","unstructured":"Kewan T, Mirza A, Pine AB, Rasheed Y, Hamouche R, L\u00e9veill\u00e9 E, et al. CAR T-related toxicities based on dynamic proteomic profiles identifies risk factors for cytokine release syndrome (CRS) and immune effector cell -associated neurotoxicity syndrome (ICANS). Blood. 2023;142:2132.","journal-title":"Blood"},{"key":"3913_CR21","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/nrn2722","volume":"10","author":"AR Jones","year":"2009","unstructured":"Jones AR, Overly CC, Sunkin SM. The Allen brain atlas: 5 years and beyond. Nat Rev Neurosci. 2009;10:821\u20138.","journal-title":"Nat Rev Neurosci"},{"key":"3913_CR22","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1158\/2326-6066.CIR-22-0418","volume":"10","author":"JP Tang","year":"2022","unstructured":"Tang JP, Peters CW, Quiros C, Wang X, Klomhaus AM, Yamada R, et al. Hypophosphatemia due to increased effector cell metabolic activity is associated with neurotoxicity symptoms in CD19-Targeted CAR T-cell therapy. Cancer Immunol Res. 2022;10:1433\u201340.","journal-title":"Cancer Immunol Res"},{"key":"3913_CR23","doi-asserted-by":"publisher","first-page":"11663","DOI":"10.1182\/blood-2022-170579","volume":"140","author":"E Jabbour","year":"2022","unstructured":"Jabbour E, Paul S, Nichols D, Darbaniyan F, Lee J, Sasaki K, et al. Incidence of central nervous system toxicity and cytokine release syndrome in leukemia patients treated with blinatumomab. Blood. 2022;140:11663\u20135.","journal-title":"Blood"},{"key":"3913_CR24","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3390\/ph13060124","volume":"13","author":"S Niyongere","year":"2020","unstructured":"Niyongere S, Petitto GS, Masur J, Baer MR, Duong VH, Emadi A. Frontline blinatumomab in older adults with philadelphia chromosome-negative B-cell acute lymphoblastic leukemia. Pharmaceuticals (Basel). 2020;13:124.","journal-title":"Pharmaceuticals (Basel)"},{"key":"3913_CR25","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","volume":"127","author":"A Viardot","year":"2016","unstructured":"Viardot A, Goebeler M, He\u00df G, Neumann S, Pfreundschuh M, Adrian N, et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma. Blood. 2016;127:1410\u20136.","journal-title":"Blood"},{"key":"3913_CR26","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1177\/2040620716640422","volume":"7","author":"JE Benjamin","year":"2016","unstructured":"Benjamin JE, Stein AS. The role of blinatumomab in patients with relapsed\/refractory acute lymphoblastic leukemia. Ther Adv Hematol. 2016;7:142\u201356.","journal-title":"Ther Adv Hematol"},{"key":"3913_CR27","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","volume":"6","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Cao J, Cheng H, Qiao J, Zhang H, Wang Y, et al. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol. 2019;6:e521\u20139.","journal-title":"Lancet Haematol"},{"key":"3913_CR28","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009038","volume":"96","author":"Y Liu","year":"2017","unstructured":"Liu Y, Li K, Huang Y, Sun J, Gao X. Treatment of the superior sagittal sinus and transverse sinus thrombosis associated with intracranial hemorrhage with the mechanical thrombectomy and thrombolytics. Medicine (Baltimore). 2017;96: e9038.","journal-title":"Medicine (Baltimore)"},{"key":"3913_CR29","doi-asserted-by":"publisher","first-page":"e2368","DOI":"10.1212\/WNL.0000000000201122","volume":"99","author":"L Shu","year":"2022","unstructured":"Shu L, Bakradze E, Omran SS, Giles J, Amar J, Henninger N, et al. Predictors of recurrent venous thrombosis after cerebral venous thrombosis: analysis of the ACTION-CVT study. Neurology. 2022;99:e2368\u201377.","journal-title":"Neurology"},{"key":"3913_CR30","doi-asserted-by":"crossref","unstructured":"Filippidou M, Avgerinou G, Katsibardi, Gavra M, Pons R, Kattamis A. Delayed-onset severe neurotoxicity related to blinatumomab in an adolescent patient with refractory acute lymphoblastic leukemia. Pediatr Blood Cancer. 2021;68:0\u20130.","DOI":"10.1002\/pbc.29040"},{"key":"3913_CR31","first-page":"1352","volume":"31","author":"M Ouyang","year":"2023","unstructured":"Ouyang M, Zhang Y, Shi L, Liu J, Wang C, Wang F, et al. Clinical study of blinatumomab in the treatment of adult relapsed\/refractory Ph-negative acute B-lymphoblastic leukemia. PubMed. 2023;31:1352\u20137.","journal-title":"PubMed"},{"key":"3913_CR32","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1182\/blood-2018-99-117400","volume":"132","author":"M Alfayez","year":"2018","unstructured":"Alfayez M, Kantarjian HM, Short NJ, Assi R, Khouri M, Ravandi F, et al. Safety and efficacy of blinatumomab in patients with central nervous system (CNS) disease: a single institution experience. Blood. 2018;132:2702.","journal-title":"Blood"},{"key":"3913_CR33","doi-asserted-by":"publisher","first-page":"414177563","DOI":"10.1177\/2040620719899897","volume":"11","author":"T Jain","year":"2020","unstructured":"Jain T, Litzow MR. Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia. Ther Adv Hematol. 2020;11:414177563.","journal-title":"Ther Adv Hematol"},{"key":"3913_CR34","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00277-018-3497-0","volume":"98","author":"AS Stein","year":"2018","unstructured":"Stein AS, Schiller GJ, Benjamin R, Jia C, Zhang A, Zhu M, et al. Neurologic adverse events in patients with relapsed\/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors. Ann Hematol. 2018;98:159\u201367.","journal-title":"Ann Hematol"},{"key":"3913_CR35","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13054-023-04787-x","volume":"28","author":"I Urbino","year":"2024","unstructured":"Urbino I, Lengline E, Valade S, Cerrano M, Sebert M, Raffoux E, et al. Life-threatening complications and intensive care unit management in patients treated with blinatumomab for B-cell acute lymphoblastic leukemia. Crit Care. 2024;28:14.","journal-title":"Crit Care"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-03913-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-03913-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-03913-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T10:42:50Z","timestamp":1738838570000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-025-03913-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3913"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-03913-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5298514\/v1","asserted-by":"object"}]},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]},"assertion":[{"value":"20 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required as the study was conducted using de-identified publicly available data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"72"}}